The company has a diverse and highly experienced Board, committed to seeing the Sienna diagnostic tests adopted by the medical profession and researchers, providing a genuine benefit to the public. The Board consists of three members, each with significant commercial and management experience:

Geoff Cumming Chairman

Geoff Cumming, BSc (Hons), BAppSc, MAICD, MBA, PhD, Chairman of Sienna, was appointed to the Sienna Board in 2006. Geoff has held senior roles in the global healthcare and biotechnology sector for more than 20 years. As Managing Director, Roche Diagnostic Systems (Oceania), Geoff transformed the loss-making entity the Swiss parent was intending to divest, into the fastest growing and most profitable affiliate in the Roche group. In his role as Managing Director/CEO of Biosceptre International Ltd, Geoff was successful in designing and securing key funding arrangements through a skilful range of capital raising initiatives, including large government grants, partnering and co-development deals.

His most recent executive role was as Managing Director / CEO of Anteo Diagnostics Ltd (ASX: ADO). He is currently a Non-executive Director of Anteo Diagnostics Ltd and was previously a Non-executive Director of Medical Australia Ltd (ASX: MLA), until November 2017.

Carl Stubbings Chief Executive Officer and Managing Director 

Carl Stubbings, BSc, joined Sienna’s Board in December 2011 and was appointed CEO/Managing Director on 16 October 2019. Carl has considerable experience commercialising diagnostic products, both locally and globally. Based in the USA for 13 years, he served as Senior Vice President for Panbio USA Ltd and Vice-President of Sales and Marketing for Focus Diagnostics, a subsidiary of Quest Diagnostics, one of the world’s largest pathology laboratories. In July 2012, Carl moved back to Australia where he was appointed Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC). More recently he has been assisting several Australian biotech companies with their commercialisation strategies. These companies include BCAL Diagnostics, a start-up company developing a blood test for breast cancer, Minomic, an Immuno Oncology company with a test for prostate cancer, and Biotron (ASX: BIT), a listed company that is developing and commercialising anti-viral small molecule therapies.

Carl was previously a Non-executive Director of ASX listed medical device company Analytica Medical Limited (ASX:ALT), until November 2017.

Helen Fisher Non-Executive Director

Helen Fisher, BSc, LLB (Hons), LLM, MCom, is a passionate leader with a rare combination of financial expertise and deep knowledge and global networks in the Life Sciences industry. Helen is CEO and Managing Director of Bio Capital Impact Fund and a director of NovellusDx, a personalised cancer diagnostics company. Prior to establishing the Fund, Helen was a partner of Deloitte and led Deloitte’s Life Sciences industry practice in Australia for 5 years, having had many years’ experience in the Life Sciences and Health Care industry. She also specialised in the Financial Services Industry, servicing some of the largest banks and funds in the Funds Management industry and has been involved in setting up a number of large international funds, as well as advised on a number of significant M&A deals.

Helen provided strategic tax advice to publicly listed and large multinational companies and has extensive experience with capital raisings, licensing deals, demergers, implementing offshore structures, IP management and location, and supply chain management. Helen has Bachelor degrees in Law (with Honours) and Science from the University of Melbourne, a Masters degree in Laws (specialising in International Taxation) from the University of Melbourne and a Masters degree in Commerce from the University of NSW. Helen is a Chartered Tax Adviser and an affiliate member of Chartered Accountants Australia and New Zealand. Helen is the Chair of the Victorian branch of AusBiotech.

Sign up for updates